Fig. 5
From: A novel lipophilic amiloride derivative efficiently kills chemoresistant breast cancer cells
LLC1 is well tolerated by mice. Adult Balb/cJ mice were injected intraperitoneally with 0–45 mg/kg LLC1 on days 0, 3 and 6 of the study and sacrificed on day 7. (A) Body weights were recorded throughout the study. (B) A blood chemistry panel illustrates the effects of repeated LLC1 treatment on liver (ALT, alanine transaminase; AST, aspartate transaminase; albumin; alk phos, alkaline phosphatase; total bilirubin; total protein) and kidney (BUN, blood urea nitrogen; creatinine; total protein) markers. Reference values taken from 95% intervals for female BALB/c mice at Charles River’s standard production setting (BALBcMouseClinicalPathologyData.pdf). Images of mouse (C) spleen, (D) heart, (E) liver, and (F) kidneys are displayed for each dose after formalin fixation.
